A comprehensive view of Health Care Reform. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

New Cardinal Health research finds 80% of oncologists believe inequities exist throughout healthcare that lead to differences in access, time to diagnosis, treatment; 60% say a bias exists toward non-white, Latinx patients

Berenberg upgrades Merck to buy from hold and raises target by US$5 to US$100, says shares could jump 17% thanks to low exposure to US drug price reform and Inflation Reduction Act, both of which pose significant threats to pharmaceutical sector

GlobalData forecasts US pharmaceutical sales of prescription/nonprescription drugs to hit US$624B in 2023, but expects few pharmaceutical companies to be left unaffected by Medicare’s planned negotiation on US drug prices, which go into full effect 2026

Fitch: Generic drugs facing challenges in US due to pricing pressures; lawmakers have outlined buying cheap, foreign-made generics, particularly within state-subsidized healthcare schemes, will become essential tool in ensuring better access to healthcare

Moody's: US drug pricing reform in Inflation Reduction Act may have credit-lowering effect on industry; it’s unclear which drugs costs will get negotiated, but potential candidates include drugs from Bristol Myers, Pfizer, Eli Lilly, AbbVie, J&J, Gilead

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count